{
    "clinical_study": {
        "@rank": "45417", 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF)\n      buprenorphine/naloxone combination tablet administration and determine whether outcomes are\n      improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one\n      in which take-home doses are given on intervening days."
        }, 
        "brief_title": "Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2", 
        "completion_date": {
            "#text": "August 1997", 
            "@type": "Actual"
        }, 
        "condition": [
            "Heroin Dependence", 
            "Opioid-Related Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heroin Dependence", 
                "Opioid-Related Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Mon/Wed/Fri dosing with the 8 mg buprenorphine/naloxone tablet is as safe and effective as\n      daily dosing and is preferred by patients to daily dosing.  Multiple doses of the\n      combination tablet (e.g. 16mg, 24mg) are well tolerated by patients.  A 3 day schedule with\n      take-outs is as effective as a 3-day schedule in which all medication is ingested at the\n      clinic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Individual must be currently dependent and meet FDA criteria for narcotic maintenance\n        treatment.  Co-morbid substance abuse or dependence disorders may also be present.\n        Individuals must be healthy despite drug dependency.\n\n        Exclusion Criteria:\n\n        Individuals with evidence of an active Diagnostic and Statistical Manual of Mental\n        Disorders (DSM-IV) Axis I psychiatric disorder (e.g., psychosis, manic-depressive illness,\n        organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular\n        disease) or pregnant female subjects are excluded from study participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "62 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000327", 
            "org_study_id": "NIDA-11160-2", 
            "secondary_id": [
                "R01DA011160", 
                "R01-11160-2"
            ]
        }, 
        "intervention": {
            "intervention_name": "Heroin Dependence", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Analgesics, Opioid", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80206"
                }, 
                "name": "University of Colorado Health Sciences Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2)", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Leslie Amass, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 1997", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Drug use"
            }, 
            {
                "measure": "Retention"
            }, 
            {
                "measure": "Compliance"
            }, 
            {
                "measure": "Dosing schedule preferences"
            }, 
            {
                "measure": "Analog rating scale for dosing schedule effects"
            }
        ], 
        "reference": {
            "citation": "Amass, L., Kamien, J.H., and Mikulich, S.K. Efficacy of and preference for 3-day vs daily dosing with the buprenorphine-naloxone combination tablet. presented to the 1998 Meeting of the College on Problems of Drug Dependence. Scottsdate, AZ (6/13-18). Presenting at CPDD 1998"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000327"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 1997", 
        "study_design": "Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }, 
    "geocoordinates": {
        "University of Colorado Health Sciences Center": "39.739 -104.985"
    }
}